AACHEN, Germany, February 18, 2013 /PRNewswire/ --
Oscar Ferenczi, former Region Head of Sandoz Latin America, takes over responsibility for Grünenthal's Strategic Business Unit (SBU) LATAM.
Today, the Grünenthal Group announced the appointment of Oscar Ferenczi to Executive Vice President for the SBU Grünenthal Latin America with immediate effect. In his responsibility he will also take over the task of General Manager Grünenthal S.A. Panama, the regional head office of the company in Latin America, as well as General Manger Grünenthal Latin America, Miami. As a member of the Group Operating Committee of the pain specialist headquartered in Aachen (Germany), Oscar Ferenczi will be based in Miami, Florida, and will report directly to Grünenthal Group Chief Executive Officer, Harald F. Stock, Ph.D.
"Strengthening our businesses in Latin America is one of our core strategic objectives as we are aiming to generate 40 percent of Grünenthal's commercial business from the region in 2015. I am glad that Oscar has decided to lead the Group's Strategic Business Unit with its ambitious, dedicated, and passionate people. He joins Grünenthal with a successful track record in general management, marketing, sales and finance in both the generics and patented segments of the pharmaceutical industry," commented Harald F. Stock, Ph.D., CEO of the Grünenthal Group.
Oscar Ferenczi, Executive Vice President SBU LATAM, is looking forward to his new position at Grünenthal: "I am excited about joining Grünenthal and the opportunity to lead the team into a driving force in Latin America. Given the potential of the region and the opportunities that exist, I see Grünenthal's strategic plans as the basis for its overall success and positioning in the region."
Excellent position for further growth - both organic and external
In Latin America, Grünenthal is further strengthening the business in these fast-growth emerging markets with selected acquisitions and licensing deals. Following the successful acquisition and integration of the Brazilian company Selfarma in 2011, Grünenthal announced in June 2012 an exclusive agreement with US-based Horizon Pharma for the commercialization of DUEXIS® in Latin America. The company's current leading market position in Latin America is mainly based on a strong portfolio in pain, Grünenthal's global core competence along with strong regional products.
More information about Grünenthal: http://www.grunenthal.com
Additional information for editorial offices: Oscar Ferenczi's CV can be downloaded on our website:
Contact: Frank Schönrock, Vice President Corporate Affairs
Tel.: +49-241-569-1568, Fax: +49-241-569-3539, email@example.com
Grünenthal GmbH, 52099 Aachen, Deutschland, http://www.grunenthal.com
SOURCE Grunenthal GmbH